title: CysLT(1)R antagonists inhibit tumor growth in a xenograft model of colon cancer.
abstract: The expression of the inflammatory G-protein coupled receptor CysLT1R has been shown to be upregulated in colon cancer patients and associated with poor prognosis. The present study investigated the correlation between CysLT1R and colon cancer development in vivo using CysLT1R antagonists (ZM198,615 or Montelukast) and the nude mouse xenograft model. Two drug administration regimens were established. The first regimen was established to investigate the importance of CysLT1R in tumor initiation. Nude mice were inoculated with 50 µM CysLT1R antagonist-pretreated HCT-116 colon cancer cells and received continued treatment (5 mg/kg/day, intraperitoneally). The second regimen aimed to address the role of CysLT1R in tumor progression. Nude mice were inoculated with non-pretreated HCT-116 cells and did not receive CysLT1R antagonist treatment until recordable tumor appearance. Both regimens resulted in significantly reduced tumor size, attributed to changes in proliferation and apoptosis as determined by reduced Ki-67 levels and increased levels of p21(WAF/Cip1) (P<0.01), cleaved caspase 3, and the caspase-cleaved product of cytokeratin 18. Decreased levels of VEGF (P<0.01) and reduced vessel size (P<0.05) were also observed, the latter only in the ZM198,615-pretreatment group. Furthermore, we performed a series of in vitro studies using the colon cancer cell line HCT-116 and CysLT1R antagonists. In addition to significant reductions in cell proliferation, adhesion and colony formation, we observed induction of cell cycle arrest and apoptosis in a dose-dependent manner. The ability of Montelukast to inhibit growth of human colon cancer xenograft was further validated by using two additional colon cancer cell lines, SW-480 and HT-29. Our results demonstrate that CysLT1R antagonists inhibit growth of colon cancer xenografts primarily by reducing proliferation and inducing apoptosis of the tumor cells.
authors.affiliation: Division of Cell and Experimental Pathology, Department of Laboratory Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.
authors.forename: Sayeh
authors.initials: S
authors.lastname: Savari
authors.forename: Minghui
authors.initials: M
authors.lastname: Liu
authors.forename: Yuan
authors.initials: Y
authors.lastname: Zhang
authors.forename: Wondossen
authors.initials: W
authors.lastname: Sime
authors.forename: Anita
authors.initials: A
authors.lastname: Sjölander
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D003106:Colon / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D005260:Female; D045325:HCT116 Cells; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D051379:Mice; D008819:Mice, Nude; D018077:Receptors, Leukotriene / Q000378:metabolism*
chemical_list: D020024:Leukotriene Antagonists; D018077:Receptors, Leukotriene; C083169:leukotriene D4 receptor
references.citation: Int J Cancer. 2011 Jul 1;129(1):9-22
references.pmid: 20824707
references.citation: Br J Pharmacol. 2008 Feb;153(3):568-82
references.pmid: 18059327
references.citation: Eur Respir J. 2008 Jan;31(1):143-78
references.pmid: 18166595
references.citation: J Clin Invest. 2002 May;109(10):1373-80
references.pmid: 12021253
references.citation: N Engl J Med. 1990 Nov 1;323(18):1228-33
references.pmid: 2215606
references.citation: Oncol Rep. 2007 Jul;18(1):99-104
references.pmid: 17549353
references.citation: Cancer. 2001 Feb 15;91(4):854-62
references.pmid: 11241255
references.citation: Keio J Med. 2010;59(1):10-8
references.pmid: 20375653
references.citation: Oncogene. 2006 Oct 26;25(50):6660-5
references.pmid: 16715140
references.citation: FASEB J. 2008 Oct;22(10):3525-36
references.pmid: 18591367
references.citation: Gastroenterology. 2000 Oct;119(4):1007-18
references.pmid: 11040187
references.citation: Mol Med Rep. 2010 Mar-Apr;3(2):245-51
references.pmid: 21472229
references.citation: Bioorg Med Chem Lett. 1998 Mar 3;8(5):453-8
references.pmid: 9871597
references.citation: Proc Natl Acad Sci U S A. 1980 Jul;77(7):4354-8
references.pmid: 6933488
references.citation: Thorax. 1984 Jul;39(7):500-4
references.pmid: 6463929
references.citation: N Engl J Med. 2007 Nov 1;357(18):1841-54
references.pmid: 17978293
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Eur J Cancer. 2010 Mar;46(4):826-35
references.pmid: 20064706
references.citation: Mol Cancer Ther. 2006 Nov;5(11):2716-26
references.pmid: 17121918
references.citation: J Biol Chem. 2003 Nov 14;278(46):45577-85
references.pmid: 12912998
references.citation: Carcinogenesis. 2005 Apr;26(4):827-34
references.pmid: 15637091
references.citation: PLoS One. 2010 Dec 28;5(12):e14439
references.pmid: 21203429
references.citation: Pulm Pharmacol Ther. 2001;14(1):3-19
references.pmid: 11162414
references.citation: Inflammation. 1996 Aug;20(4):413-25
references.pmid: 8872504
references.citation: Antiviral Res. 2006 Feb;69(2):53-9
references.pmid: 16337014
references.citation: Cancer Metastasis Rev. 2011 Dec;30(3-4):363-85
references.pmid: 22134655
references.citation: Nature. 1999 Jun 24;399(6738):789-93
references.pmid: 10391245
references.citation: PLoS One. 2012;7(7):e41786
references.pmid: 22848603
references.citation: J Biol Chem. 2005 Apr 8;280(14):13538-44
references.pmid: 15657050
references.citation: Int J Cancer. 2010 Dec 15;127(12):2893-917
references.pmid: 21351269
references.citation: Scand J Gastroenterol Suppl. 1990;172:13-8
references.pmid: 1972294
references.citation: J Pharmacol Sci. 2009 Feb;109(2):285-92
references.pmid: 19234368
references.citation: Gastroenterology. 2003 Jan;124(1):57-70
references.pmid: 12512030
references.citation: Am Rev Respir Dis. 1982 Sep;126(3):449-51
references.pmid: 7125334
references.citation: Cell Adh Migr. 2009 Apr-Jun;3(2):179-81
references.pmid: 19287215
references.citation: Neurosci Lett. 2004 Jun 17;363(3):247-51
references.pmid: 15182953
references.citation: Pharmacol Rev. 2003 Mar;55(1):195-227
references.pmid: 12615958
references.citation: J Allergy Clin Immunol. 2004 Nov;114(5):1093-9
references.pmid: 15536415
references.citation: Urology. 2009 Apr;73(4):916-21
references.pmid: 19167045
references.citation: J Biol Chem. 2002 Jun 7;277(23):20820-4
references.pmid: 11932261
references.citation: J Pharmacol Exp Ther. 1987 Nov;243(2):557-64
references.pmid: 2824752
references.citation: Nat Rev Cancer. 2010 Mar;10(3):181-93
references.pmid: 20168319
references.citation: Cancer Res. 2007 Oct 1;67(19):9190-8
references.pmid: 17909024
references.citation: Eur J Pharmacol. 1990 Dec 4;191(3):273-80
references.pmid: 1964905
references.citation: Eur J Pharmacol. 2006 Oct 24;548(1-3):158-66
references.pmid: 16949072
references.citation: J Natl Cancer Inst. 2004 Jun 16;96(12):946-56
references.pmid: 15199114
references.citation: Ann N Y Acad Sci. 1988;524:162-80
references.pmid: 2837952
references.citation: J Biol Chem. 2000 Sep 29;275(39):30531-6
references.pmid: 10851239
references.citation: Arthritis Rheum. 1994 Jan;37(1):93-7
references.pmid: 8129769